« Return to News | Drug Sponsors

Merck commits to sharing study protocols

Tuesday, July 5, 2011 12:24 PM

Merck will voluntarily include the research protocol and statistical analysis plan among the materials it supplies to medical journals when it submits clinical study manuscripts for publication, according to a PharmaTimes report.

The update to its publications policy is part of Merck’s “continuing, voluntary commitment to increase transparency about how it conducts business,” the company said. Previously, it submitted only research protocols and statistical analysis plans to journals on request. 

Once a medical journal has accepted a Merck manuscript for publication, the company will give the journal the opportunity to post on its web site, at the journal’s own discretion, the key sections of the research protocol.

These would include the objectives and hypotheses, patient inclusion and exclusion criteria, study design and procedures, efficacy and safety measures, the statistical analysis plan and any amendments relating to those sections, the company said.

“To ensure that information proprietary to the company is not made available publicly,” though, Merck will require certain sections, including the ‘background’ and ‘rationale’ parts of the study protocol, to be redacted before they are posted on a journal’s web site.

“The company will, however, always provide the full, non-redacted protocol to journal editors,” it added.

Proactive sharing of study protocols “will enhance the exchange of ideas within the scientific and medical community and ultimately lead to a better understanding of the benefits and risks of our products among health care professionals and patients,” said Dr. Michael Rosenblatt, Merck executive vice president and chief medical officer.
Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.